Understanding and manipulating programmed cell death (PCD) pathways to facilitate lymphoid tumor killing by CAR T cells

了解和操纵程序性细胞死亡 (PCD) 途径以促进 CAR T 细胞杀死淋巴肿瘤

基本信息

  • 批准号:
    10326860
  • 负责人:
  • 金额:
    $ 68.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-01-07 至 2025-12-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Recent advances using CAR T cells in lymphoid malignancies have made it clear that manipulation of the host immune system can radically alter the course of a cancer. Although there have been lifesaving responses in some patients, all too many patients have inadequate responses. Some patients and tumor types have been more amenable to CAR T cell therapies than others, despite similar levels of antigen expression, uniformity, and density. The exact mechanisms by which CAR T cells induce tumor cell death are unknown, and may be due to a combination of multiple T cell effector functions that ultimately result in cell death, potentially by triggering programmed cell death in tumor cells. Our overall hypothesis is that CAR T cells mediate tumor cell death by inducing programmed cell death (PCD) pathways in target cells. A logical corollary of this hypothesis is that one potential mechanism of resistance, which has received scant attention, is genetic or functional resistance to PCD in the target tumor cells. Furthermore, we hypothesize that the state of PCD constituents in tumor cells confers sensitivity or resistance to T-cell mediated killing, and that this relative resistance can be overcome with drugs that enhance PCD signaling in tumor cells. Finally, because systemically administered drugs that enhance PCD signaling may also affect CAR T cells, we propose genetic engineering approaches to render CAR T cells resistant to candidate PCD-enhancing drugs. This is a collaborative project between an expert in CAR T cells and immunology and an expert in programmed cell pathways and tumor biology. Together we aim to define the effector functions of T cells that induce tumor cell death (Aim 1), define the programmed cell death pathways in tumors that confer sensitivity or resistance to CAR T cell mediated killing (Aim 2), and use innovative strategies to enhance CAR T cell killing of tumor cells by manipulating PCD pathways using small molecule drugs in combination with genetic engineering of the CAR T cells.
项目摘要 在淋巴恶性肿瘤中使用CAR T细胞的最新进展已经清楚地表明,操纵宿主 免疫系统可以从根本上改变癌症的进程。尽管在过去的几年里, 有些病人,太多的病人没有充分的反应。一些患者和肿瘤类型已经 比其他细胞更适合CAR-T细胞疗法,尽管抗原表达水平,均匀性, 和密度。CAR T细胞诱导肿瘤细胞死亡的确切机制是未知的,并且可能是未知的。 由于多种T细胞效应器功能的组合最终导致细胞死亡,可能通过 引发肿瘤细胞的程序性细胞死亡。我们的总体假设是CAR T细胞介导肿瘤细胞 通过诱导靶细胞中的程序性细胞死亡(PCD)途径死亡。这一假设的逻辑推论 一种潜在的抗性机制是遗传的或功能性的, 对靶肿瘤细胞中PCD的抗性。此外,我们假设,PCD成分的状态, 肿瘤细胞赋予对T细胞介导的杀伤的敏感性或抗性,并且这种相对抗性可以是 用增强肿瘤细胞中PCD信号的药物来克服。最后,因为系统管理 增强PCD信号传导的药物也可能影响CAR T细胞,我们提出了基因工程方法, 使CAR T细胞对候选PCD增强药物具有抗性。这是一个合作项目, 他是CAR T细胞和免疫学方面的专家,也是程序化细胞通路和肿瘤生物学方面的专家。 我们的目标是共同定义T细胞诱导肿瘤细胞死亡的效应子功能(目标1), 肿瘤中的程序性细胞死亡途径赋予对CAR T细胞介导的杀伤的敏感性或抗性 (Aim 2),并使用创新策略通过操纵PCD来增强CAR T细胞对肿瘤细胞的杀伤 使用小分子药物与CAR T细胞的基因工程相结合的途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Marcela Valderrama Maus其他文献

Marcela Valderrama Maus的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Marcela Valderrama Maus', 18)}}的其他基金

CAR T cells targeting mesothelin and secreting bispecific antibodies targeting fibroblasts in pancreatic cancer
CAR T 细胞靶向间皮素并分泌靶向胰腺癌成纤维细胞的双特异性抗体
  • 批准号:
    10731635
  • 财政年份:
    2023
  • 资助金额:
    $ 68.91万
  • 项目类别:
Understanding and manipulating programmed cell death (PCD) pathways to facilitate lymphoid tumor killing by CAR T cells
了解和操纵程序性细胞死亡 (PCD) 途径以促进 CAR T 细胞杀死淋巴肿瘤
  • 批准号:
    10540403
  • 财政年份:
    2021
  • 资助金额:
    $ 68.91万
  • 项目类别:
Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel
阿那白滞素预防对接受 axicabtagene ciloleucel 的淋巴瘤患者的神经毒性和细胞因子释放综合征的疗效和免疫作用
  • 批准号:
    10241440
  • 财政年份:
    2020
  • 资助金额:
    $ 68.91万
  • 项目类别:
Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel
阿那白滞素预防对接受 axicabtagene ciloleucel 的淋巴瘤患者的神经毒性和细胞因子释放综合征的疗效和免疫作用
  • 批准号:
    10621271
  • 财政年份:
    2020
  • 资助金额:
    $ 68.91万
  • 项目类别:
Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel
阿那白滞素预防对接受 axicabtagene ciloleucel 的淋巴瘤患者的神经毒性和细胞因子释放综合征的疗效和免疫作用
  • 批准号:
    10403583
  • 财政年份:
    2020
  • 资助金额:
    $ 68.91万
  • 项目类别:
Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel
阿那白滞素预防对接受 axicabtagene ciloleucel 的淋巴瘤患者的神经毒性和细胞因子释放综合征的疗效和免疫作用
  • 批准号:
    10034347
  • 财政年份:
    2020
  • 资助金额:
    $ 68.91万
  • 项目类别:
Overcoming tumor heterogeneity in glioblastoma with multi-targeted CAR T cells secreting bispecific antibodies
利用分泌双特异性抗体的多靶点 CAR T 细胞克服胶质母细胞瘤的肿瘤异质性
  • 批准号:
    10021622
  • 财政年份:
    2019
  • 资助金额:
    $ 68.91万
  • 项目类别:
Overcoming tumor heterogeneity in glioblastoma with multi-targeted CAR T cells secreting bispecific antibodies
利用分泌双特异性抗体的多靶点 CAR T 细胞克服胶质母细胞瘤的肿瘤异质性
  • 批准号:
    10685596
  • 财政年份:
    2019
  • 资助金额:
    $ 68.91万
  • 项目类别:
Overcoming tumor heterogeneity in glioblastoma with multi-targeted CAR T cells secreting bispecific antibodies
利用分泌双特异性抗体的多靶点 CAR T 细胞克服胶质母细胞瘤的肿瘤异质性
  • 批准号:
    10237348
  • 财政年份:
    2019
  • 资助金额:
    $ 68.91万
  • 项目类别:
Overcoming tumor heterogeneity in glioblastoma with multi-targeted CAR T cells secreting bispecific antibodies
利用分泌双特异性抗体的多靶点 CAR T 细胞克服胶质母细胞瘤的肿瘤异质性
  • 批准号:
    10469337
  • 财政年份:
    2019
  • 资助金额:
    $ 68.91万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 68.91万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 68.91万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 68.91万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 68.91万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 68.91万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 68.91万
  • 项目类别:
    Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 68.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 68.91万
  • 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 68.91万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 68.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了